A. Hellmann

发表

Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.

W. Jędrzejczak, A. Tomaszewska, J. Wachowiak, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Modulation of the activity of calcium-activated neutral proteases (calpains) in chronic lymphocytic leukemia (B-CLL) cells.

J. Witkowski, E. Bryl, K. Lewandowski, 2002, Blood.

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

M. Dyer, T. Kipps, S. Stilgenbauer, 2015, Haematologica.

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

M. Dyer, T. Kipps, S. Stilgenbauer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High dose chemotherapy combined with transplantation of haematopoietic progenitor cells in the treatment of resistant and recurrent Hodgkin's disease

J. Czyż, W. Knopińska-Posłuszny, K. Lewandowski, 2000 .

First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.

J. Myśliwska, P. Trzonkowski, A. Krzystyniak, 2009, Clinical immunology.

The Time is Crucial for Ex Vivo Expansion of T Regulatory Cells for Therapy

P. Witkowski, J. Myśliwska, P. Trzonkowski, 2011, Cell transplantation.

in chronic lymphocytic leukemia (B-CLL) cells Modulation of the activity of calcium-activated neutral proteases (calpains)

J. Witkowski, K. Lewandowski, A. Hellmann, 2013 .

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

J. Radich, H. Kantarjian, A. Countouriotis, 2007, Blood.

Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo‐HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: A retrospective, multicenter Polish Adult Leukemia Group study

W. Jędrzejczak, K. Sułek, K. Kuliczkowski, 2015, American journal of hematology/oncology.

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

A. Dmoszyńska, A. Skotnicki, A. Hellmann, 2001, Haematologica.

Efficacy and Safety of Fludarabine and Cyclophosphamide Combined Therapy in Patients with Refractory/Recurrent B-Cell Chronic Lymphocytic Leukaemia (B-CLL)—Polish Multicentre Study

K. Kuliczkowski, A. Dmoszyńska, J. Kłoczko, 2004, Leukemia & lymphoma.

Recommendations for the diagnosis and treatment of patients with polycythaemia vera

R. Kusec, M. Griesshammer, M. Sever, 2018, European journal of haematology.

Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique

A. Hellmann, A. Leszczyńska, M. Bieniaszewska, 2016, Acta Haematologica.

JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.

J. Limon, Anna Siemiątkowska, A. Hellmann, 2010, Leukemia research.

Myeloproliferative Neoplasms – Classification, Diagnostic and Therapeutic Options in the Light of Molecular Findings

A. Hellmann, M. Bieniaszewska, 2009 .

Myeloproliferative syndromes: diagnosis and therapeutic options.

A. Hellmann, 2008, Polskie Archiwum Medycyny Wewnetrznej.

Quality of Life After Kidney Transplantation: A Prospective Study.

A. Dębska-Ślizień, J. Kobiela, M. Lichodziejewska-Niemierko, 2016, Transplantation proceedings.

Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study

B. Coiffier, S. Leprêtre, M. V. van Oers, 2010, British journal of haematology.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

E. Santagostino, L. Boggio, K. Fischer, 2016, Blood.

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

B. Coiffier, S. Leprêtre, M. V. van Oers, 2008, Blood.

Treatment of Graft-versus-Host Disease with Naturally Occurring T Regulatory Cells

J. Myśliwska, P. Trzonkowski, A. Dukat-Mazurek, 2013, BioDrugs.

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation.

J. Snowden, P. Dreger, A. Bosi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi‐agent chemotherapy

J. Walewski, A. Engert, N. Siritanaratkul, 2018, British journal of haematology.

First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4

J. Zaucha, W. Knopińska-Posłuszny, J. Walewski, 2019, British journal of haematology.

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

J. Zaucha, T. Gooley, W. Prejzner, 2005, Bone Marrow Transplantation.

Allogeneic stem cell transplantation in chronic myelogenous leukemia - experience of the center in Gdańsk

J. Zaucha, K. Halaburda, A. Hellmann, 2003 .

Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Jesús Martín Sánchez, M. Beksac, H. Goldschmidt, 2018, Clinical lymphoma, myeloma & leukemia.

ICON: Eosinophil Disorders

T. Haferlach, K. Sotlar, A. Reiter, 2012, The World Allergy Organization journal.

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

J. Radich, F. Giles, G. Saglio, 2021, Leukemia.

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

M. Baccarani, R. Clark, K. Indrák, 2015, Leukemia.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

W. Wiktor-Jedrzejczak, F. Giles, G. Saglio, 2017, Leukemia.

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

W. Wiktor-Jedrzejczak, T. Brümmendorf, M. Baccarani, 2015, Leukemia.

Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine.

K. Sułek, A. Tomaszewska, J. Góra‐Tybor, 2004, European journal of cancer.

Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

W. Jędrzejczak, K. Sułek, T. Robak, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cholecystectomy after endoscopic retrograde cholangiopancreatography – effect of time on treatment outcomes

R. Pęksa, J. Kobiela, Z. Śledziński, 2018, Przeglad gastroenterologiczny.

Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study

W. Jędrzejczak, I. Seferyńska, A. Skotnicki, 2008, British journal of haematology.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

A. López-Guillermo, F. Bosch, A. Nagler, 2019, The Lancet. Haematology.

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

T. Haferlach, K. Sotlar, A. Reiter, 2012, The Journal of allergy and clinical immunology.

CONSENSUS DOCUMENT ICON : Eosinophil Disorders

Eld, T. Haferlach, K. Sotlar, 2022 .

Excessive amount and activity of μ-calpain affects apoptotic machinery in chronic B-cell leukemia cells and influences the course of the disease.

T. Fulop, J. Witkowski, E. Bryl, 2020, Acta biochimica Polonica.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

N. Schmitz, H. Heimpel, H. Döhner, 2015, Leukemia.

A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy.

A. Dmoszyńska, I. Špička, J. Kłoczko, 2007, Haematologica.

Clinical assessment of Optivate®, a high‐purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A

T. Baglin, M. Makris, K. Kuliczkowski, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Beneficial effect of the CXCL12-3'A variant for patients undergoing hematopoietic stem cell transplantation from unrelated donors.

W. Jędrzejczak, A. Tomaszewska, D. Duda, 2015, Cytokine.

Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma

M. Dimopoulos, S. Lonial, R. Foà, 2012, International Journal of Hematology.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

M. Heuser, J. Cortes, B. Smith, 2018, Leukemia.

Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant

W. Knopińska-Posłuszny, J. Walewski, L. Gil, 2013, Leukemia & lymphoma.

Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis

P. Boguradzki, W. Knopińska-Posłuszny, J. Walewski, 2013, Annals of Hematology.

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

A. Hagenbeek, M. Czuczman, J. Radford, 2012, Blood.

Clinical characteristics of essential thrombocythemia patients depend on the mutation status

W. Prejzner, A. Hellmann, A. Mital, 2020 .

Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy

W. Jędrzejczak, A. Nagler, P. Smolewski, 2004, Bone Marrow Transplantation.

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

M. Baccarani, G. Rosti, K. Indrák, 2013, Leukemia.

Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream

J. Kur, B. Nowicki, S. Nowicki, 2013, European Journal of Clinical Microbiology & Infectious Diseases.

Cytogenetic analysis and clinical significance of chromosome 7 aberrations in acute leukaemia.

A. Wozniak, J. Limon, A. Balcerska, 2003, Journal of applied genetics.

Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome

A. Piekarska, L. Gil, W. Prejzner, 2015, Annals of Hematology.

Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years

W. Wiktor-Jedrzejczak, M. Labopin, K. Indrák, 2009, Annals of Hematology.

A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group

T. Robak, K. Kuliczkowski, A. Dmoszyńska, 2005, Annals of Hematology.

A multicenter, open, non‐comparative, phase II study of the combination of cladribine (2‐chlorodeoxyadenosine), cytarabine, and G‐CSF as induction therapy in refractory acute myeloid leukemia – a report of the Polish Adult Leukemia Group (PALG)

T. Robak, K. Kuliczkowski, A. Dmoszyńska, 2003, European journal of haematology.

Trisomy 13 in a case of myelodysplastic syndrome.

J. Limon, A. Hellmann, W. Baran, 1989, Cancer genetics and cytogenetics.

Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: Analysis of prognostic factors and comparison with a single procedure

R. Dziadziuszko, J. Czyż, A. Skotnicki, 2007, Leukemia & lymphoma.

Molecular Methods in Myeloproliferative Neoplasms

W. Prejzner, A. Hellmann, A. Leszczyńska, 2012 .

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

A. Hagenbeek, P. Sonneveld, J. Radford, 2008, Blood.

The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; The results of multicenter, prospective Polish adult leukemia group study

K. Kuliczkowski, A. Wierzbowska, A. Skotnicki, 2011, American journal of hematology.

Autoimmune haemolytic anaemia in patients with chronic lymphocytic eukaemia treated with 2‐chlorodeoxyadenosine (cladribine)

M. Błasińska-Morawiec, T. Robak, L. Konopka, 1997, European journal of haematology.

2‐Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7‐year experience in Poland

M. Błasińska-Morawiec, T. Robak, A. Dmoszyńska, 1999, European journal of haematology.

Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.

M. Majewski, A. Skotnicki, K. Warzocha, 2009, Polskie Archiwum Medycyny Wewnetrznej.

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

M. Baccarani, H. Kantarjian, J. Cortes, 2015, Cancer.

2-Chlorodeoxyadenosine treatment in the Sezary syndrome.

J. Zaucha, K. Lewandowski, A. Hellmann, 1997, Blood.

Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sézary syndrome.

K. Mrózek, J. Lubiński, J. Limon, 1995, Cancer genetics and cytogenetics.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

T. Brümmendorf, G. Rosti, N. Cross, 2015, Journal of Cancer Research and Clinical Oncology.

A randomized, open‐label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

J. Byrd, I. Flinn, F. Awan, 2014, British journal of haematology.

Safety and efﬁcacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

B. Coiffier, S. Leprêtre, T. Robak, 2008 .

2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature.

J. Zaucha, K. Halaburda, K. Lewandowski, 2000, Medical science monitor : international medical journal of experimental and clinical research.

Effect of a 2‐hour infusion of 2‐chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia

J. Zaucha, T. Robak, K. Halaburda, 1999, European journal of haematology.

Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine‐based regiments or chlorambucil – follow‐up of PALG‐CLL randomized trials

K. Sułek, I. Seferyńska, J. Góra‐Tybor, 2013, European journal of haematology.

Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients

W. Jędrzejczak, A. Tomaszewska, J. Wachowiak, 2014, American journal of hematology.

IL-10 promoter polymorphisms influence susceptibility to aGvHD and are associated with proportions of CD4+FoxP3+ lymphocytes in blood after hematopoietic stem cell transplantation.

W. Jędrzejczak, J. Nowak, K. Warzocha, 2013, Tissue antigens.

Imatinib targeted therapy for a patient with chronic eosinophilic leukemia

J. Limon, W. Prejzner, A. Hellmann, 2005 .

NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.

W. Jędrzejczak, J. Nowak, K. Warzocha, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

M. Tormo, M. Voso, J. Cavenagh, 2021, Blood advances.

[Thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus successfully treated with plasma exchange and corticosteroids].

K. Sworczak, A. Hellmann, P. Wiśniewski, 2007, Polskie Archiwum Medycyny Wewnetrznej.

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript

J. Limon, K. Halaburda, W. Prejzner, 2006, Bone Marrow Transplantation.

Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics

A. Blom, M. Okrój, A. Felberg, 2019, Cancer Immunology, Immunotherapy.

Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donors

J. Zaucha, P. Trzonkowski, A. Piekarska, 2022, Immunity & Ageing.

Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non‐Hodgkin’s lymphoma receiving combination chemotherapy

A. Österborg, J. Mayer, A. Hellmann, 2007, British journal of haematology.

Successful Use of Nilotinib in the Therapy of a Patient with a Chemoresistant Relapse of BCR-ABL1-Like Phenotype Acute Lymphoblastic Leukemia

A. Piekarska, A. Hellmann, M. Libura, 2018, Oncology Research and Treatment.

Pseudo-stroke manifestation of multiple myeloma: a report of two cases with literature review.

K. Sworczak, T. Szmuda, P. Czapiewski, 2013, Folia Neuropathologica.

High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group

K. Sułek, R. Dziadziuszko, A. Nagler, 2002, Bone Marrow Transplantation.

Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera - retrospective analysis of 142 consecutive cases.

W. Prejzner, A. Hellmann, A. Mital, 2015, Thrombosis research.

The Effect of ATRA (Roche) on Clinical and Laboratory Parameters in 36 APL Patients — Polish Multicenter Retrospective Analysis

K. Sułek, T. Robak, Z. Kuratowska, 1998 .

Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).

W. Jędrzejczak, K. Sułek, T. Robak, 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

prospective, randomized, multicenter trial first-line therapy in chronic lymphocytic leukemia: report of a Cladribine with prednisone versus chlorambucil with prednisone as

M. Błasińska-Morawiec, A. Dmoszyńska, A. Skotnicki, 2013 .

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.

M. Błasińska-Morawiec, T. Robak, A. Dmoszyńska, 2000, Blood.

Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria

M. Triggiani, A. Órfão, H. Kluin-Nelemans, 2007, European journal of clinical investigation.

Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.

J. Zaucha, P. Potemski, J. Góra‐Tybor, 1997, Leukemia & lymphoma.

Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation.

H. Johnsen, M. Mohty, A. Wåhlin, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment of multiple myeloma with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation – a single centre experience

K. Lewandowski, A. Hellmann, A. Mital, 2004 .

Treatment of multiple myeloma with high-dose chemotherapy and autologoushaematopoietic progenitor cell transplantation - a single centre experience

J. Czyż, W. Knopińska-Posłuszny, K. Lewandowski, 2002 .

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

T. Kipps, G. Gaidano, A. Schuh, 2015, The New England journal of medicine.

Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery

T. Baglin, M. Makris, A. Dmoszyńska, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management

L. Valentino, D. Quon, P. Schroth, 2012, Journal of thrombosis and haemostasis : JTH.

Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients

G. Di Minno, I. Pabinger, J. Windyga, 2012, Thrombosis and Haemostasis.

A Pharmacokinetic Study of Amphotericin B Lipid Complex Injection (Abelcet) in Patients with Definite or Probable Systemic Fungal Infections

R. Branch, A. Janoff, A. Adedoyin, 2000, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Optivate®, a high‐purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A

T. Baglin, M. Makris, K. Kuliczkowski, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy, safety and pharmacokinetic results of a phase II/III, multicentre, double-blinded, randomized, cross-over study with a plasma-derived von Willebrand Factor/factor VIII concentrate (Voncento ®) in subjects with hemophilia A (the SWIFT-HA study)

C. Joch, K. Kuliczkowski, A. Dmoszyńska, 2015 .

For Peer Review Pharmacokinetics of Optivate®, a high-purity concentrate of Factor VIII (FVIII) with von Willebrand factor (VWF), in patients with severe haemophilia A.

A. Hellmann, 2010 .

Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).

C. Joch, K. Kuliczkowski, A. Dmoszyńska, 2016, Thrombosis research.

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

Jiří Mayer, Nichola Cooper, V. Markovtsov, 2018, American journal of hematology.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Alessandro Corso, Robin Foà, M. Dimopoulos, 2007, The New England journal of medicine.

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

J. Radich, F. Giles, G. Saglio, 2018, Journal of Cancer Research and Clinical Oncology.

Effective Drug Concentration and Selectivity Depends on Fraction of Primitive Cells

A. Składanowski, M. Wieczór, K. Rolka, 2021, International journal of molecular sciences.

First report of vancomycin-resistant Enterococcus faecium isolated in Poland.

W. Hryniewicz, A. Samet, K. Trzciński, 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Isolation and epidemiological study of vancomycin-resistant Enterococcus faecium from patients of a haematological unit in Poland.

J. Kur, A. Samet, A. Hellmann, 1999, The Journal of hospital infection.

[Platelet defects in chronic myeloproliferative disorders].

J. Kabata, A. Hellmann, A. Skibowska, 1994, Acta haematologica Polonica.

Treatment of the Lymphocele After Kidney Transplantation: A Single-center Experience.

B. Rutkowski, A. Dębska-Ślizień, Z. Śledziński, 2016, Transplantation proceedings.

Prevention of hepatitis B virus transmission from an infected stem cell donor

J. Zaucha, G. McDonald, A. Piekarska, 2007, Bone Marrow Transplantation.

HLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donor.

Agnieszka Witkowska, Malgorzata Baranska, Agnieszka Tomaszewska, 2018, Human immunology.

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis

G. Rosti, N. Cross, F. Giles, 2017, Journal of Cancer Research and Clinical Oncology.

Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study

J. Walewski, E. Paszkiewicz-Kozik, A. Hellmann, 2018, Leukemia & lymphoma.

Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation

A. Piekarska, W. Prejzner, A. Hellmann, 2017, Annals of Hematology.

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib

S. Mustjoki, F. Giles, K. Porkka, 2017, Haematologica.

Comprehensive cancer-oriented biobanking resource of human samples for studies of post-zygotic genetic variation involved in cancer predisposition

A. Piotrowski, J. Dumanski, M. Wójcik, 2021, bioRxiv.

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.

P. S. Andersen, W. Jędrzejczak, T. P. Frandsen, 2012, Blood.

antibodies, in the treatment of primary immune thrombocytopenia Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD

P. S. Andersen, T. P. Frandsen, J. Windyga, 2012 .

G-CSF Administered in Time-sequenced Setting During Remission Induction and Consolidation Therapy of Adult Acute Lymphoblastic Leukemia has Beneficial Influence on Early Recovery and Possibly Improves Long-term Outcome: A Randomized Multicenter Study

T. Robak, A. Dmoszyńska, A. Skotnicki, 2002, Leukemia & lymphoma.

Epidemiology of toxocariasis – environmental investigations

F. Tost, A. Hellmann, G. Ockert, 1998, Der Ophthalmologe.

Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field

Torsten Haferlach, Peter Vandenberghe, Jason Gotlib, 2012, Expert review of hematology.

[Toxocara canis infection. Environmental parasitologic and epidemiologic studies].

F. Tost, A. Hellmann, G. Ockert, 1998, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

Rituximab (Mabthera™, rituxan™) in patients with recurrent indolent lymphoma

J. Zaluski, J. Czyż, K. Kuliczkowski, 2001, Medical oncology.

The use of Tenckhoff catheters for draining of symptomatic lymphoceles: a review of literature and our experience.

A. Dębska-Ślizień, Z. Śledziński, I. Marek, 2015, Transplantation proceedings.

Endoscopic management of early GI tract bleeding in a group of bariatric patients undergoing a fast track protocol

I. Marek, J. Bigda, Ł. Kaska, 2020, Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques.

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

W. Jędrzejczak, K. Sułek, T. Robak, 2004, Leukemia.

Surgical decompression of Wirsung duct reduces serum concentration of SPINK1 in patients with chronic pancreatitis.

C. Bassi, S. Paiella, Z. Śledziński, 2018, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Multiple red cell alloantibodies, including anti‐Dib, after allogeneic ABO‐matched peripheral blood progenitor cell transplantation

J. Zaucha, B. Michalewska, E. Brojer, 2005, Transfusion.

Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease

A. Piekarska, L. Bieniaszewski, K. Halaburda, 2005, Bone Marrow Transplantation.

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.

K. Sułek, I. Seferyńska, J. Góra‐Tybor, 2006, Blood.

Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine--a report of three cases.

M. Błasińska-Morawiec, T. Robak, A. Hellmann, 1997, Leukemia & lymphoma.

2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.

J. Zaucha, M. Błasińska-Morawiec, T. Robak, 1996, Leukemia & lymphoma.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

W. Wilson, I. Pastan, J. Delgado, 2018, Leukemia.

CCR5 gene polymorphism affects the risk of GvHD after haematopoietic stem cell transplantation from an unrelated donor

W. Jędrzejczak, D. Duda, A. Kucharska, 2015, British journal of haematology.

Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients.

W. Jędrzejczak, A. Skotnicki, A. Wrzesień-kuś, 2005, Transplantation proceedings.

Acquired von Willebrand Syndrome During the Course of Myelofibrosis: Analysis of 32 Cases.

W. Prejzner, A. Hellmann, A. Mital, 2015, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients.

W. Prejzner, A. Hellmann, A. Mital, 2015, Polskie Archiwum Medycyny Wewnetrznej.

Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.

J. Radich, S. Acharyya, F. Giles, 2018 .

Association of cytokine gene polymorphisms with the complications of allogeneic haematopoietic stem cell transplantation.

P. Trzonkowski, A. Dukat-Mazurek, G. Moszkowska, 2017, Human immunology.

[Prolymphocytic leukemia - case report].

A. Hellmann, 1981, Acta haematologica Polonica.

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia

J. Byrd, U. Jaeger, F. Awan, 2016, British journal of haematology.

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

I. Seferyńska, J. Góra‐Tybor, T. Robak, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re‐treatment with cladribine‐based regimens in relapsed patients with B‐cell chronic lymphocytic leukemia

J. Góra‐Tybor, T. Robak, A. Dmoszyńska, 2002, European journal of haematology.

Influence of Chromosomal Aberrations on Response to First Line Therapy in B-Cell Chronic Lymphocytic Leukemia: Interim Analysis of PALG-CLL3 Randomized Study Comparing Cladribine Plus Cyclophosphamide vs Fludarabine Plus Cyclophosphamide.

J. Góra‐Tybor, T. Robak, A. Dmoszyńska, 2007 .

Randomized Comparison of Cladribine Plus Cyclophsophamide with Fludarabine Plus Cyclophosphamide in Progressive Chronic Lymphocytic Leukemia: An Updated Report of Prospective PALG-CLL3 Study.

K. Sułek, I. Seferyńska, J. Góra‐Tybor, 2006 .

Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients

J. Zaucha, J. Myśliwska, P. Trzonkowski, 2004, Medical oncology.

Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia

H. Heimpel, J. Hasford, A. Ganser, 2014, Journal of Cancer Research and Clinical Oncology.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

M. Höglund, M. Baccarani, K. Indrák, 2017, Leukemia.

The Overexpression of KIT Proto-Oncogene in Acute Leukemic Cells Is Not Necessarily Caused by the Gene Mutation

A. Hellmann, D. Szatkowski, 2014, Acta Haematologica.

Case report Insufficiency of the pituitary gland resulting from the central nervous system infiltration in cours of non-Hodgkin's DLBCL lymphoma recurrence

K. Sworczak, M. Taszner, A. Hellmann, 2014 .

Insufficiency of the pituitary gland resulting from central nervous system infiltration in course of non-Hodgkin ’ s DLBCL lymphoma recurrence

K. Sworczak, M. Taszner, A. Hellmann, 2014 .

Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors

A. Piekarska, L. Gil, W. Prejzner, 2016, Contemporary oncology.

HuMax CD20 Fully Human Monoclonal Antibody in Chronic Lymphocytic Leuchemia. Early Results from an Ongoing Phase I/II Clinical Trial.

B. Coiffier, H. Tilly, T. Robak, 2005 .

HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody

A. Hagenbeek, P. Sonneveld, J. Radford, 2005 .

Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.

K. Sułek, R. Dziadziuszko, A. Nagler, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Idarubicin, Cytarabine, Etoposide Versus Risk-Adjusted Daunorubicin Plus Cytosine Arabinoside for Induction Treatment of Acute Myeloid Leukemia: A Randomized Multicenter Trial

Z. Kuratowska, A. Dmoszyńska, A. Skotnicki, 1997 .

Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.

K. Halaburda, A. Hellmann, 1994, Acta haematologica Polonica.

Glutathiones-transferase activity of leukemic cells as a prognostic factor for response to chemotherapy in acute leukemias

A. Hellmann, J. Koberda, 1991, Medical oncology and tumor pharmacotherapy.

Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.

J. Zaucha, W. Prejzner, A. Hellmann, 2006, Clinical and laboratory haematology.

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma

K. Sułek, T. Robak, A. Dmoszyńska, 2004, British Journal of Cancer.

Production of Colony Stimulating Activity in Mixed Mononuclear Cell Culture

J. Goldman, A. Hellmann, K. H. Th'ng, 1980, British journal of haematology.

Fludarabine Therapy in Waldenström's Macroglobulinemia Patients Treated Previously with 2-chlorodeoxyadenosine

K. Halaburda, K. Lewandowski, A. Hellmann, 2002, Leukemia & lymphoma.

Microscopic examination of bone marrow aspirates in malignant disorders of haematopoiesis—a comparison of two slide preparation techniques

K. Lewandowski, A. Hellmann, A. Complak, 2011, Annals of Hematology.

Ureteric Stenting in Kidney Transplant Recipients, Gdansk Centre Experience, Poland.

A. Dębska-Ślizień, Z. Śledziński, S. Hać, 2018, Transplantation proceedings.

Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.

A. Hellmann, H. Ciepłuch, W. Baran, 2002, Medical science monitor : international medical journal of experimental and clinical research.

Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second‐Line Therapy: A Multicenter Prospective Observational Study

J. Góra‐Tybor, T. Sacha, S. Kyrcz‐Krzemień, 2017, Clinical lymphoma, myeloma & leukemia.

Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin’s Lymphoma

J. Walewski, O. Shpilberg, S. Rule, 2011, Clinical pharmacokinetics.

2‐Chlorodeoxyadenosine (cladribine)‐related eosinophilia in patients with lymphoproliferative diseases

M. Błasińska-Morawiec, T. Robak, Z. Kuratowska, 1997, European journal of haematology.

Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.

J. Zaucha, P. Potemski, T. Robak, 2009, Leukemia & lymphoma.

Incidence of CML in Europe -- a Comparison of 19 European Countries with US SEER Data

J. Hasford, M. Baccarani, R. Clark, 2014 .

Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients

H. Heimpel, M. Bangerter, M. Griesshammer, 1996, Annals of Hematology.

Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study

J. Roh, A. Madani, P. Parida, 2023, The Lancet Diabetes & Endocrinology.

Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study.

J. Radich, W. Wiktor-Jedrzejczak, F. Giles, 2016 .

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom

J. Radich, F. Giles, G. Saglio, 2020 .

Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study.

J. Radich, S. Acharyya, F. Giles, 2019, Journal of Clinical Oncology.

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib

A. Piskorz, J. Limon, K. Lewandowski, 2011, European journal of haematology.

Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma.

J. Rossi, A. Hagenbeek, M. Czuczman, 2009 .

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

M. Dyer, T. Kipps, S. Stilgenbauer, 2009 .

The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL.

U. Jaeger, X. Thomas, E. Koller, 2012, European journal of cancer.

Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy.

T. Kipps, W. Wierda, A. Österborg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Graft-versus-Host Disease with Naturally Occurring T Regulatory Cells

J. Myśliwska, P. Trzonkowski, A. Dukat-Mazurek, 2013, BioDrugs.

Erythrophagocytosis by neutrophils – a rare morphological phenomenon resulting in acquired haemolytic anaemia?

K. Lewandowski, A. Hellmann, A. Mital, 2011, International journal of laboratory hematology.

HuMax-CD20 Fully Human Monoclonal Antibody in Follicular Lymphoma. First Human Exposure: Early Results of an Ongoing Phase I/II Trial.

A. Hagenbeek, T. Plesner, J. Walewski, 2004 .

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

A. Risitano, A. Lundberg, G. Ramsingh, 2015 .

Diagnosis of Klinefelter syndrome in the donor after peripheral blood stem cell transplantation

K. Halaburda, I. Brożek, A. Hellmann, 2000, Bone Marrow Transplantation.

Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens

D. Niederwieser, P. Dreger, E. Holler, 2019, Biology of Blood and Marrow Transplantation.

Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study

I. Seferyńska, T. Robak, A. Dmoszyńska, 2009, Leukemia & lymphoma.

Multiple malignancies and Richter's transformation in patient with small lymphocytic B-cell lymphoma - diagnostic and therapeutic dilemmas

P. Czapiewski, A. Piekarska, A. Hellmann, 2013 .

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results

P. Bartolomeo, A. Guarini, R. Mesa, 2017 .

Emerging linezolid-resistant, vancomycin resistant Enterococcus faecium from a patient of a haematological unit in Poland.

J. Kur, A. Samet, B. Krawczyk, 2004, Polish journal of microbiology.

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results

R. Mesa, A. Vannucchi, M. McMullin, 2016 .

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

M. Tormo, M. Voso, J. Cavenagh, 2021, Blood advances.

Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream

J. Kur, B. Nowicki, S. Nowicki, 2013, European Journal of Clinical Microbiology & Infectious Diseases.

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

R. Greil, H. Döhner, M. Minden, 2015, Blood.

Loss of Y in regulatory T lymphocytes in the tumor micro-environment of primary colorectal cancers and liver metastases

M. Wójcik, Marek Zdrenka, Łukasz Szylberg, 2023, medRxiv.

Fibrinogen Gdansk: hypofibrinogenemia associated with a novel missense mutation in FGA (Ser112Pro).

M. Neerman-Arbez, A. Undas, A. Hellmann, 2012, Thrombosis research.

Severe complication of acquired hemophilia: active bleeding into the gallbladder resulting in cholecystitis requiring surgery.

Z. Śledziński, S. Hać, A. Hellmann, 2015, Polskie Archiwum Medycyny Wewnetrznej.

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

R. Greil, A. Chanan-Khan, W. Brugger, 2019, Blood.

Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial.

J. Cortes, J. Lipton, T. Schenk, 2016, Journal of Clinical Oncology.

90Y-Zevalin® (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation of FCM Induction Chemotherapy in Mantle Cell Lymphoma (MCL) Patients: Results from the PLRG upon Completed Enrollment.

A. Hubalewska-Dydejczyk, A. Sowa-Staszczak, A. Skotnicki, 2006 .